Q4 highlights: all-time-high revenue with growth in all areas
Consumables up +47% vs 2020, +23% vs Q3 2021 and above pre-pandemic levels
Instrument sales increasing globally
Continued strong sales in USA driven by OEM
Disturbances in the supply chain
Good progress with our strategic priorities
COVID
recovery
Positive R12 trends for both instruments and consumables continues
Boule Diagnostics
February 3, 2022
Increased profitability
Net sales in constant currencies up +50% YoY
Growth in all product lines and regions
Region and product mix, but mainly supply chain disturbances pressure gross margin
Investments in new platform 15 MSEK
Boule Diagnostics
February 3, 2022
Financials Q4
Net sales, MSEK
Gross margin
140.3
41.2%
YoY Growth
EBIT-margin
51.4%
9.9%
Op. cash-flow, MSEK
11.8
Sales bridge: growth in all areas
Recovery driven by easing of pandemic restrictions across the world
OEM business continue to show strong performance
Growth in US driven mainly by OEM business
Asia growth driven by instrument and consumable sales to India. Still restrictions in many other countries
Eastern Europe, positive impact from start of local production
Increased initiatives in Africa/Middle East starting to generate results
Boule Diagnostics
February 3, 2022
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Boule Diagnostics AB published this content on 03 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 February 2022 09:48:06 UTC.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
